Evidence map›Paper›PMID 26432848›Full record

ArticleNeurology2015

Survival in synucleinopathies: A prospective cohort study.

David S Goldstein, Courtney Holmes, Yehonatan Sharabi, Tianxia Wu

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 2 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 2 syntheses or guidelines pooled it, 101 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Exploring the relationship between orthostatic hypotension and gait in people with Parkinson's disease.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2025
    Article
  8. Article
  9. Review
  10. Review
  11. Impact of autonomic symptoms on the clinical course of Parkinson's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Article
  12. Abnormal Cerebrovascular Activity, Perfusion, and Glymphatic Clearance in Lewy Body Diseases.Movement disorders : official journal of the Movement Disorder Society · 2024
    Review
  13. Hypotensive episodes at 24-h ambulatory blood pressure monitoring predict adverse outcomes in Parkinson's disease.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2024
    Article
  14. Article
  15. Review
  16. Review
  17. CardiacClinical autonomic research : official journal of the Clinical Autonomic Research Society · 2023
    Review
  18. Article
  19. Review
  20. Burden of caregiving for cardiovascular dysautonomia in Parkinson's disease.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2022
    Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

David S GoldsteinFrom the Clinical Neurocardiology Section (D.S.G., C.H.) and Office of the Clinical Director (T.W.), Clinical Neurosciences Program, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD; and Hypertension Unit (Y.S.), Chaim Sheba Medical Center and Tel Aviv University, Tel HaShomer, Israel. goldsteind@ninds.nih.gov.
Courtney HolmesFrom the Clinical Neurocardiology Section (D.S.G., C.H.) and Office of the Clinical Director (T.W.), Clinical Neurosciences Program, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD; and Hypertension Unit (Y.S.), Chaim Sheba Medical Center and Tel Aviv University, Tel HaShomer, Israel.
Yehonatan SharabiFrom the Clinical Neurocardiology Section (D.S.G., C.H.) and Office of the Clinical Director (T.W.), Clinical Neurosciences Program, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD; and Hypertension Unit (Y.S.), Chaim Sheba Medical Center and Tel Aviv University, Tel HaShomer, Israel.
Tianxia WuFrom the Clinical Neurocardiology Section (D.S.G., C.H.) and Office of the Clinical Director (T.W.), Clinical Neurosciences Program, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD; and Hypertension Unit (Y.S.), Chaim Sheba Medical Center and Tel Aviv University, Tel HaShomer, Israel.
Sheba Medical Center · IL

Funding

Intramural NIH HHS
6 · The paper itself

Abstract

objectivesParkinson disease (PD), multiple system atrophy (MSA), and pure autonomic failure (PAF) involve cytoplasmic deposition of α-synuclein and are considered to be synucleinopathies. Approximately 40% of patients with PD, most patients with MSA, and all patients with PAF have neurogenic orthostatic hypotension (OH). This study compared long-term survival in these synucleinopathies.

methodsIn this prospective cohort study, survival data were obtained for 97.6% of 206 referred patients evaluated between 1994 and 2014 (47 PD + OH, 54 PD no OH, 15 cerebellar MSA [MSA-C], 57 parkinsonian MSA [MSA-P], 28 PAF). Individual diagnoses were confirmed by clinical criteria and results of pharmacologic, neurochemical, and neuroimaging tests of sympathetic noradrenergic innervation. The Cox proportional hazard model was used to calculate hazard ratios (HRs) from symptom onset and from time of evaluation to death.

resultsPatients with MSA-C or MSA-P had shorter survival from symptom onset than did patients with PD + OH (age- and sex-adjusted HR = 6.1, 5.6; p < 0.0001 each), PAF (HR = 10.8, 9.9; p < 0.0001 each) or PD no OH (HR = 14.9, 13.6; p < 0.0001 each). Among parkinsonian patients who died, median times from motor onset to death were 7.5 years in MSA-P, 11.6 years in PD + OH, and 15.8 years in PD no OH. Probabilities of survival for 10 years from onset of relevant symptoms were 0.39 in MSA-C, 0.33 in MSA-P, 0.74 in PD + OH, 0.87 in PAF, and 0.93 in PD no OH.

conclusionsIn synucleinopathies, survival depends on the particular disease, with the risk of death greater in MSA-P than in PD + OH and in PD + OH than in PD no OH.

Indexed as

Agedalpha-SynucleinBrainCerebellar DiseasesCohort StudiesDihydroxyphenylalanineFemaleFluorine RadioisotopesHumansLongitudinal StudiesMaleMiddle AgedMultiple System AtrophyParkinson DiseaseParkinsonian DisordersProportional Hazards Modelsalpha-SynucleinDihydroxyphenylalanineFluorine Radioisotopes

Identifiers

PMID26432848
PMCPMC4642141
OpenAlexW2176885794

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.